Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multi-state battle to stop sales of replica ...

Eli Lilly & Co. failed to prove in a federal court that a business selling copycat versions of its obesity drug causes harm ...

Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical ...

Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India ・Tirzepatide is used to manage type 2 ...

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

BDF-GESTION sold 4,149 shares of Eli Lilly ( LLY 0.58%) stock during the quarter. The estimated transaction value was $3.09 million, using the average unadjusted closing price for the quarter. After ...

Indian drugmaker Cipla Limited has entered into a strategic marketing and distribution agreement with US pharma major Eli ...